TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05881473

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: pain assessment after clavicular fracture repair
Description: This group includes (40) patients will have medial and lateral clavipectoral (CPB) block ultrasound guided using 20 ml Bupivacaine 0.5% for medial and lateral block equally after induction of general anesthesia.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: pain assessment after clavicular fracture repair
Description: This group includes (40) patients will have medial and lateral clavipectoral (CPB) block ultrasound guided using 20 ml Bupivacaine 0.5% for medial and lateral block equally after induction of general anesthesia.
Study: NCT06082011

Intervention type: DEVICE
Intervention: da Vinci SP Surgical System
Description: Model and specification: SP1098 Manufacturer: Intuitive Surgical, Inc.
Study: NCT06520709

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06028945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HMD: Virtual Reality Exposure Therapy
Description: The virtual reality exposure therapy uses 360-degree videos delivered through a head mounted display (HMD). Participants will be matched with one of three available exposure hierarchies: Social Party Scenario, Subway Scenario, or Shopping Mall Scenario. Each hierarchy comprises seven 5-min scenes ordered in increasing intensity (from low to high anxiety). Participants are gradually exposed to scenes, viewed twice per day for up to 10 days, while rating their anxiety immediately before and after the exposures. Anxiety ratings will inform when participants may advance to the next level intensity in the exposure hierarchy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HMD: Neutral Game
Description: The neutral game is a virtual-reality based game that is not designed to provoke anxiety. Participants assigned to the neutral game will play for 5 minutes twice per day for up to 10 days.
Study: NCT05640245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonelokimab
Description: randomized treatment; parallel group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonelokimab
Description: randomized treatment; parallel group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonelokimab
Description: randomized treatment; parallel group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: randomized treatment; parallel-group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: randomized treatment; parallel-group
Study: NCT05639556

Intervention type: DIAGNOSTIC_TEST
Intervention: BMI and lean mass index from DXA
Description: Estimate and compare correlation between lean mass index from DXA and BMI

Intervention type: DIAGNOSTIC_TEST
Intervention: BMI and lean mass index from DXA
Description: Estimate and compare correlation between lean mass index from DXA and BMI

Intervention type: DIAGNOSTIC_TEST
Intervention: Anthropometric Measurements
Description: Skinfold will be assessed with calipers. Circumference will be measured with a tape measure.
Study: NCT05169424

Intervention type: DEVICE
Intervention: Trelegy Ellipta
Description: Trelegy Ellipta

Intervention type: DEVICE
Intervention: Stiolto Respimat
Description: Stiolto Respimat

Intervention type: DRUG
Intervention: Tiotropium + Olodaterol (5/5 mcg)
Description: Tiotropium + Olodaterol (5/5 mcg)

Intervention type: DRUG
Intervention: Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)
Description: Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)
Study: NCT05854979

Intervention type: DIAGNOSTIC_TEST
Intervention: Gastric Ultrasound
Description: A gastric ultrasound will be completed on every patient and administered the same way in each arm. The patient will be placed in supine position. A curvilinear ultrasound probe will be placed on the sagittal plane below the xiphoid process. The probe will then slide along the costal margin to the right until the gastric antrum is identified. At this point, the ultrasound image will be obtained, and appropriate measurements will be taken. The patient will be placed in the right lateral decubitus position and the above procedure will be repeated.

Intervention type: DIAGNOSTIC_TEST
Intervention: Gastric Ultrasound
Description: A gastric ultrasound will be completed on every patient and administered the same way in each arm. The patient will be placed in supine position. A curvilinear ultrasound probe will be placed on the sagittal plane below the xiphoid process. The probe will then slide along the costal margin to the right until the gastric antrum is identified. At this point, the ultrasound image will be obtained, and appropriate measurements will be taken. The patient will be placed in the right lateral decubitus position and the above procedure will be repeated.
Study: NCT05616338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: A blood sample and a nasal brush for each participant. The nasal brushing will allow the isolation of epithelial cells that will serve as a comparison for the bronchial tissue produced from blood-derived iPS.~A blood sample of approximately 14 ml will be taken for isolation and freezing of the blood mononuclear cells allowing the generation of iPS.
Study: NCT05639556

Intervention type: DIAGNOSTIC_TEST
Intervention: Anthropometric Measurements
Description: Skinfold will be assessed with calipers. Circumference will be measured with a tape measure.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hand-grip strength
Description: A small, handheld dynamometer will be used to measure grip strength, a measure of function, on each hand.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hand-grip strength
Description: A small, handheld dynamometer will be used to measure grip strength, a measure of function, on each hand.

Intervention type: DIAGNOSTIC_TEST
Intervention: Six-minute walk Test
Description: This will be another functional assessment of fitness. Participants will be asked to walk at their normal pace for 6 minutes.The total distance walked in that time will be measured.
Study: NCT05751707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency Chest Wall Oscillations via The Vest® Airway Clearance System
Description: High Frequency Chest Wall Oscillations via The Vest® Airway Clearance System is a clinical device which consists in a pump which generates high frequency oscillations and connected to a jacket worn by the patient, intended to facilitate airway secretions clearance by detaching them from the bronchial wall and moving them upwards in the bronchial system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency Chest Wall Oscillations via The Vest® Airway Clearance System
Description: High Frequency Chest Wall Oscillations via The Vest® Airway Clearance System is a clinical device which consists in a pump which generates high frequency oscillations and connected to a jacket worn by the patient, intended to facilitate airway secretions clearance by detaching them from the bronchial wall and moving them upwards in the bronchial system.
Study: NCT05639556

Intervention type: DIAGNOSTIC_TEST
Intervention: Six-minute walk Test
Description: This will be another functional assessment of fitness. Participants will be asked to walk at their normal pace for 6 minutes.The total distance walked in that time will be measured.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sit-to-Stand Test
Description: This will be used as a functional assessment of fitness and lower extremity strength. Participants will start seated on a chair and be asked to complete as many sit-to-stand repetitions without using their arms for one minute.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sit-to-Stand Test
Description: This will be used as a functional assessment of fitness and lower extremity strength. Participants will start seated on a chair and be asked to complete as many sit-to-stand repetitions without using their arms for one minute.

Intervention type: DIAGNOSTIC_TEST
Intervention: Short physical performance battery (SPPB)
Description: This is an assessment of frailty. The test is completed in approximately 8 minutes. The test consists of 3 assessments: 1) Balance tests where the participant stands and tries to balance with their feet in various positions for 10 seconds each without assistance (side-by-side, heel-to-side, and heel-to-toe); 2) Two 4-meter gait speed tests; and 3) Chair-stand tests (single chair stand, 5 chair stands).

Intervention type: DIAGNOSTIC_TEST
Intervention: Short physical performance battery (SPPB)
Description: This is an assessment of frailty. The test is completed in approximately 8 minutes. The test consists of 3 assessments: 1) Balance tests where the participant stands and tries to balance with their feet in various positions for 10 seconds each without assistance (side-by-side, heel-to-side, and heel-to-toe); 2) Two 4-meter gait speed tests; and 3) Chair-stand tests (single chair stand, 5 chair stands).

Intervention type: DIAGNOSTIC_TEST
Intervention: BIA Sub-study
Description: A minimum of 50 individuals will be enrolled. Body composition will be assessed at each study visit using study bioelectrical impendence analysis (BIA).

Intervention type: DIAGNOSTIC_TEST
Intervention: BIA Sub-study
Description: A minimum of 50 individuals will be enrolled. Body composition will be assessed at each study visit using study bioelectrical impendence analysis (BIA).

Intervention type: DIAGNOSTIC_TEST
Intervention: Accelerometry to assess physical activity
Description: Participants will be provided with a wrist-worn accelerometer/heart rate monitor at the baseline study visit and asked to wear it continuously for at least 3-10 days (two weekdays, one weekend day). Approximately every 3 months, the participant will be asked to again wear the accelerometer. Participants will be able to keep their accelerometers.
Study: NCT05977023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMDAE
Description: Use of an NMDA enhancer for the treatment of bipolar depression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cap
Description: Use of placebo as a comparator.
Study: NCT05806996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: Intravenous infusion, load 50 mg/Kg with infusion of 15 mg/Kg/hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent volume of normal saline
Study: NCT06252883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serial bedside video call communication
Description: Bedside video call with audio features, given to NICU parent/guardian 2-3 days a week for an 8-week period or till infant is discharged, whichever comes first.
Study: NCT04722497

Intervention type: OTHER
Intervention: Sound Education
Description: All physicians and nurses involved in cesarean births will be given an education intervention explaining the impact of noise levels on stress and focus. The SoundEar device will be used as an intervention tool to inform operating room physicians and nurses when the noise level is above the desired level.
Study: NCT05870189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote CMR
Description: 12 weeks of remote CMR is done 3x/week, 45 min/session.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Remote Exercise
Description: 12 weeks of remote exercise is done 3x/week, 45 min/session.
Study: NCT05148091

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: A Recombinant Trimeric S Protein Vaccine against SARS-CoV-2 Alpha and Beta Variants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: A Recombinant Trimeric S Protein Vaccine against SARS-CoV-2 Alpha and Beta Variants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: A Recombinant Trimeric S Protein Vaccine against SARS-CoV-2 Alpha and Beta Variants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: A Recombinant Trimeric S Protein Vaccine against SARS-CoV-2 Alpha and Beta Variants

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Adjuvant
Description: SCT-VA02B is the adjuvant of SCTV01C VACCINE applied as one of the control in the trial

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Adjuvant
Description: SCT-VA02B is the adjuvant of SCTV01C VACCINE applied as one of the control in the trial

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Adjuvant
Description: SCT-VA02B is the adjuvant of SCTV01C VACCINE applied as one of the control in the trial

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Adjuvant
Description: SCT-VA02B is the adjuvant of SCTV01C VACCINE applied as one of the control in the trial

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is used as the other control in the trial
Study: NCT05998577

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESM and Traqq
Description: Two telephone applications: ESM is a psychosocial diary and Traqq is a food diary to measure abdominal pain as well as possible triggerfactors (i.e. diet, stress, anxiety)
Study: NCT06351059

Intervention type: DIAGNOSTIC_TEST
Intervention: InModi acoustic emission analysis
Description: All diagnosis tests

Intervention type: DIAGNOSTIC_TEST
Intervention: InModi acoustic emission analysis
Description: All diagnosis tests

Intervention type: DIAGNOSTIC_TEST
Intervention: InModi acoustic emission analysis
Description: All diagnosis tests

Intervention type: DIAGNOSTIC_TEST
Intervention: InModi acoustic emission analysis
Description: All diagnosis tests

Intervention type: DIAGNOSTIC_TEST
Intervention: InModi acoustic emission analysis
Description: All diagnosis tests

Intervention type: DIAGNOSTIC_TEST
Intervention: InModi acoustic emission analysis
Description: All diagnosis tests
Study: NCT06245213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANAVEX3-71 oral capsules
Description: ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects. This novel mechanism of action offers the potential to treat all symptom domains (positive, negative, and cognitive) of schizophrenia without the side effects of standard of care antipsychotics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANAVEX3-71 oral capsules
Description: ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects. This novel mechanism of action offers the potential to treat all symptom domains (positive, negative, and cognitive) of schizophrenia without the side effects of standard of care antipsychotics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANAVEX3-71 oral capsules
Description: ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects. This novel mechanism of action offers the potential to treat all symptom domains (positive, negative, and cognitive) of schizophrenia without the side effects of standard of care antipsychotics.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsules
Description: The placebo comparator for the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsules
Description: The placebo comparator for the study.
Study: NCT05344898

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subscap Tenotomy
Description: Group will not have their subscapularis tendon repaired following a reverse shoulder replacement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subscap Repair
Description: Group will have their subscapularis tendon repaired following a reverse shoulder replacement.
Study: NCT05812014

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021)
Description: One dose was administered by intramuscular injection, 100μg，1.0ml/dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride solution
Description: One dose was administered by intramuscular injection, 1.0ml/dose
Study: NCT05148091

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is used as the other control in the trial

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is used as the other control in the trial

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is used as the other control in the trial
Study: NCT05639556

Intervention type: DIAGNOSTIC_TEST
Intervention: Accelerometry to assess physical activity
Description: Participants will be provided with a wrist-worn accelerometer/heart rate monitor at the baseline study visit and asked to wear it continuously for at least 3-10 days (two weekdays, one weekend day). Approximately every 3 months, the participant will be asked to again wear the accelerometer. Participants will be able to keep their accelerometers.

Intervention type: OTHER
Intervention: Gastrointestinal (GI) and nutrition questionnaires:
Description: Subjects will complete surveys regarding gastrointestinal (GI) symptoms, including the Patient Assessment of Constipation (PAC-SYM) Score, Patient Assessment of Gastrointestinal Symptoms (PACGI-SYM) Score, the Bristol Stool Chart, and the scored Patient-Generated Subjective Global Assessment (PG-SGA).

Intervention type: OTHER
Intervention: Gastrointestinal (GI) and nutrition questionnaires:
Description: Subjects will complete surveys regarding gastrointestinal (GI) symptoms, including the Patient Assessment of Constipation (PAC-SYM) Score, Patient Assessment of Gastrointestinal Symptoms (PACGI-SYM) Score, the Bristol Stool Chart, and the scored Patient-Generated Subjective Global Assessment (PG-SGA).
Study: NCT04817228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EscharEx (EX-02 formulation)
Description: EscharEx (EX-02 formulation) gel is topically applied on a wound surface of up to 80 cm2 , up to 8 consecutive applications or until a complete debridement is achieved, whichever occurs first.
Study: NCT05271656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Scan System
Description: Subjects will be provided with contrast agent and dietary fiber pills, and instructed to start intake of fiber pills 5 days, and contrast agent 48 hours prior to scheduled C-Scan capsule ingestion. C-Scan system intervention includes ingestion of the C-Scan Cap and attachment of the C-Scan Track to the subject's lower back. The subject is required to keep the C-Scan Track attached to the lower back and to continue intake of contrast agent and dietary fiber pills until the C-Scan Cap's natural excretion. Standard of care optical colonoscopy will be performed within 60 days from the C-Scan Cap ingestion.
Study: NCT03999840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemdisiran
Description: Cemdisiran has been designed to reduce the level of C5 mRNA in the liver, thereby reducing levels of circulating C5 protein, inhibiting terminal complement pathway activity, and preventing formation and deposition of the MAC (C5-b9) on endothelial cells in the kidney.
Study: NCT05639556

Intervention type: OTHER
Intervention: Psychosocial questionnaire: PHQ-8
Description: This is an 8-item scale that measures depressive symptoms over the past two weeks.

Intervention type: OTHER
Intervention: Psychosocial questionnaire: PHQ-8
Description: This is an 8-item scale that measures depressive symptoms over the past two weeks.
Study: NCT03999840

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The control drug for this study will be a placebo (sodium chloride 0.9% w/v for SC administration). Placebo will be prepared and labelled identically to cemdisiran.
Study: NCT05639556

Intervention type: OTHER
Intervention: Psychosocial questionnaire: GAD-7
Description: This is a 7-items scale that measures anxiety symptoms over the past two weeks, from not at all to nearly every day.

Intervention type: OTHER
Intervention: Psychosocial questionnaire: GAD-7
Description: This is a 7-items scale that measures anxiety symptoms over the past two weeks, from not at all to nearly every day.
Study: NCT04698993

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dräger Antigen Test SARS-CoV-2
Description: Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dräger Antigen Test SARS-CoV-2
Description: Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test
Study: NCT06152107

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BTVA treatment plus optimal medical therapy (GOLD guidelines)
Description: Patients in experimental group will be treated with the InterVapor System in at least 2 subsegments of different segments. Patients in control group will be treated with the InterVapor System in at least 1 segment.~A sequential procedure allows for at least 6 weeks and no longer than 6 months after the first procedure. Patients in both groups will be treated in the ipsilateral lobe in a single procedure with the air+tissue volume of at least≥500 ml and≤1,700 ml in per procedure. All patients will continue to receive optimal medical therapy (GOLD guidelines) for the duration of the study.~Follow-up visits will be scheduled at 1, 3, 6 and 12 months following the second procedure with examination of pulmonary function tests, HRCT, 6-minute walk test, SGRQ-C, mMRC, CAT questionnaires. All adverse events during the study will be recorded.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BTVA treatment plus optimal medical therapy (GOLD guidelines)
Description: Patients in experimental group will be treated with the InterVapor System in at least 2 subsegments of different segments. Patients in control group will be treated with the InterVapor System in at least 1 segment.~A sequential procedure allows for at least 6 weeks and no longer than 6 months after the first procedure. Patients in both groups will be treated in the ipsilateral lobe in a single procedure with the air+tissue volume of at least≥500 ml and≤1,700 ml in per procedure. All patients will continue to receive optimal medical therapy (GOLD guidelines) for the duration of the study.~Follow-up visits will be scheduled at 1, 3, 6 and 12 months following the second procedure with examination of pulmonary function tests, HRCT, 6-minute walk test, SGRQ-C, mMRC, CAT questionnaires. All adverse events during the study will be recorded.
Study: NCT06388798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Psychoeducational training
Study: NCT04860141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 600mg
Description: The patient will take gabapentin 600mg 2 hours prior to the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the patient will take a pill that looks like gabapentin 2 hours prior to the procedure
Study: NCT06272123

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention